SARS-COV-2 MPRO INHIBITORS AND USES THEREOF
This application relates to novel compounds and their use as SARS-CoV-2 Main Protease (Mpro) inhibitors. Compounds described herein may be useful in the treatment of SARS-CoV-2 and related viruses and disorders associated with SARS-CoV-2: Mpro. The application is also directed to pharmaceutical comp...
Saved in:
Main Authors | , , , , , |
---|---|
Format | Patent |
Language | English French |
Published |
11.04.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | This application relates to novel compounds and their use as SARS-CoV-2 Main Protease (Mpro) inhibitors. Compounds described herein may be useful in the treatment of SARS-CoV-2 and related viruses and disorders associated with SARS-CoV-2: Mpro. The application is also directed to pharmaceutical compositions comprising these compounds and the manufacture and use of these compounds and compositions in the treatment of SARS-CoV-2 and related viruses and disorders associated with SARS-CoV-2: Mpro. The compounds and compositions may be useful in preventing death or complications arising due to chronic underlying conditions or comorbidities in patients infected with SARS- CoV-2 and related viruses.
La présente demande concerne de nouveaux composés et leur utilisation en tant qu'inhibiteurs de la protéase principale du SARS-CoV-2 (Mpro). Les composés décrits ici peuvent être utiles dans le traitement du SARS-CoV-2 et de virus apparentés, ainsi que des troubles associés au SARS-CoV-2 : Mpro. La demande concerne également des compositions pharmaceutiques comprenant ces composés et la fabrication et l'utilisation de ces composés et compositions dans le traitement du SARS-CoV-2 et de virus apparentés, ainsi que des troubles associés au SARS-CoV-2 : Mpro. Les composés et les compositions peuvent être utiles dans la prévention de la mort ou des complications survenant en raison d'états sous-jacents chroniques ou de comorbidités chez des patients infectés par le SARS-CoV-2 et des virus apparentés. |
---|---|
Bibliography: | Application Number: WO2023EP77644 |